NASDAQ$SMLR

Semler Scientific Inc · Q1 2022 earnings

Q1 2022 earnings · · Investor relations

Briefing

Semler Scientific's financial results for Q1 2022 were reported with revenue increase of 6% and net income of $3.4 million.

Semler Scientific reported a revenue increase of 6% to $14.0 million and a net income of $3.4 million for the first quarter of 2022. The company's cash position increased, and a stock buyback program was initiated.

  • Revenues were $14.0 million, an increase of 6% compared to $13.2 million.
  • Net income was $3.4 million, or $0.50 per basic share and $0.41 per diluted share, compared to $4.9 million, or $0.73 per basic share and $0.60 per diluted share.
  • Cash at March 31, 2022 increased to $38.4 million from $26.5 million.
  • Up to $20.0 million stock buyback program initiated.

Headline financials

Total Revenue

$14M

Previous: $13.2M+6.3%
EPS (adj)

$0.41

Previous: $0.60-31.7%
Capital Expenditures

$122K

Previous: $133K-8.3%
Free Cash Flow

$1.38M

Previous: $4.47M-69.1%
Net Income

$3.36M

Previous: $4.88M-31.1%
Operating Income

$3.94M

Previous: $6.02M-34.5%
Gross Profit

$13M

Previous: $11.6M+12.4%
Cash & Equivalents

$38.4M

Previous: $26.5M+45.1%
Total Assets

$55.4M

Previous: $40.6M+36.4%
Stock-Based Comp

$628K

Previous: $589K+6.6%

Revenue & EPS history

Semler Scientific · Revenue · Quarterly

$14M

Q1 2022+6.3%vs Q1 2021
Beat estimate in 8 of 14 quarters(57%)
ActualEstimate

Forward guidance

Semler Scientific expects continued profitability and cash generation from operating activities, as well as increased spending to support anticipated growth in its business.

Tailwinds

  • Second quarter revenue will range from $14.2 million to $15.2 million
  • Annual revenue in 2022 will range from $58.0 million to $60.0 million
  • Continued profitability
  • Generation of cash from operating activities
  • Increased spending to support anticipated growth

Headwinds

  • Second quarter operating expense will range from $10.0 million to $10.5 million.
  • Annual operating expense will range from $44.0 million to $46.0 million.
  • Increased spending to support anticipated growth in its business.
  • Uncertainty created by the ongoing COVID-19 pandemic
  • Insurance plans and other customers may not continue to license its cardiovascular testing products

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 6 quarterly earnings reports

Historical avg

-0.2%

Avg return

Earnings day

-2.4%

Avg return

5 days after

-5.8%

Avg return

30 days after

54%

25 / 46 earnings

Positive

+33.6%

Q4 2014

Best reaction

-33.3%

Q3 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q3 2025-10.7%-16.0%-25.1%
Q2 2025-1.8%+2.0%-20.7%
Q1 2025-11.4%+17.9%-19.3%
Q4 2024+3.0%-12.4%-22.7%
Q3 2024+27.1%+29.9%+106.6%
Q2 2024-5.4%-1.7%-16.7%
Q4 2023-32.7%-36.8%-42.5%
Q3 2023+7.6%
Q2 2023+7.9%
Q1 2023+13.8%
Q4 2022+26.9%
Q3 2022-33.3%
Q2 2022+19.4%
Q1 2022-20.6%
Q4 2021-27.3%
Q3 2021-25.6%
Q2 2021-2.7%
Q1 2021+1.5%
Q4 2020+13.6%
Q3 2020+10.0%
Q2 2020-3.6%
Q1 2020-2.6%
Q4 2019+1.8%
Q3 2019+1.7%
Q2 2019+1.5%
Q1 2019-2.7%
Q4 2018+4.8%
Q3 2018-12.5%
Q2 2018+20.6%
Q1 2018+6.4%
Q4 2017+2.5%
Q3 2017+16.0%
Q2 2017-5.9%
Q1 2017+1.5%
Q4 2016+7.9%
Q3 2016-16.0%
Q2 2016+8.1%
Q1 2016-9.2%
Q4 2015-7.9%
Q3 2015+0.1%
Q2 2015-12.2%
Q1 2013+0.9%
Q4 2014+33.6%
Q3 2014-3.7%
Q2 2014-2.0%
Q1 2014+1.2%
Q4 2013
Q3 2013
Q2 2013
Q4 2012
Q3 2012

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro